Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer

BACKGROUND: Both paclitaxel (P) and carboplatin (C) have significant activity in non-small cell lung cancer (NSCLC). The weekly administration of P is active, dose intense, and has a favorable toxicity profile. We retrospectively reviewed the data of 51 consecutive patients receiving C and day 1 and...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Yumuk, Perran F, Turhal, Nazim S, Gumus, Mahmut, Hatabay, Nilgun F, Turken, Orhan, Ozkan, Alper, Salepci, Taflan, Aliustaoglu, Mehmet, Ahiskali, Rengin
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2005
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC548151/
https://ncbi.nlm.nih.gov/pubmed/15667664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-5-10
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars